Rosetta Genomics' microRNA-Based Assay For Thyroid Cancer Highlighted In Poster Presentation At 84th Annual Meeting Of The American Thyroid Association

By: via Benzinga
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that data in ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.